Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-27T12:40:27.789Z Has data issue: false hasContentIssue false
  • English
  • Français

The Effect of Sodium Valproate on Tardive Dyskinesia - Revisited

Published online by Cambridge University Press:  02 January 2018

G. G. Fisk  and
S. M. York
G. G. Fisk*
Affiliation:
Mapperley Hospital, Prochester Road, Mapperley, Nottingham, NG3 6AA
S. M. York
Affiliation:
Mapperley Hospital, Prochester Road, Mapperley, Nottingham, NG3 6AA
*
∗St John's Hospital, London Road, Lincoln LN4 2HN
Get access Rights & Permissions [Opens in a new window]

Abstract

As a treatment for tardive dyskinesia, sodium valproate was tested in a double-blind placebo-controlled parallel group trial, with 6-week base-line observation period followed by 6 weeks of treatment. Sodium valproate was not found to be an effective treatment for either tardive dyskinesia or drug-induced Parkinsonism, and did not affect mental state or behaviour.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 150 , Issue 4 , April 1987 , pp. 542 - 546
Copyright
Copyright © 1987 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andén, N. E. & Stock, G. (1973) Inhibitory effect of gamma-hydroxybutyric acid and gamma aminobutyric acid on dopamine cells in the substantia nigra. Naanyn-Schmiedeberg's Archives of Pharmacology, 297, 89–92.Google Scholar
Andén, N. E. & Wachtel, H. (1977) Biochemical effect of baclofen on the dopamine and the noradrenaline in the rat brain. Acta Pharmacologic et Toxicologic, 40, 310–320.Google Scholar
Barnes, T. R. E. & Kidger, T. (1979) Tardive dyskinesia and the problems of assessment. In Current Themes in Psychiatry (eds R. N. Gaind & B. L. Hudson) Vol II. London: Macmillan.Google Scholar
Barnes, T. R. E. & Trauer, T. (1982) Reliability and validity of a tardive dyskinesia videotape rating technique. British Journal of Psychiatry, 140, 508–515.Google Scholar
Casey, D. E. (1976) Tardive dyskinesia: are there subtypes? New England Journal of Medicine, 295, 1078.Google Scholar
Casey, D. E. & Hammerstad, J. P. (1979) Sodium valproate in tardive dyskinesia. Journal of Clinical Psychiatry, 40, 483–485.Google Scholar
Casey, D. E., Gerlach, J. Magelund, G. & Rosted Christensen, T. (1980) Gamma-acetylenic GABA in tardive dyskinesia. Archives of General Psychiatry, 37, 1376–1379.Google Scholar
Chien, C., Jung, K. & Ross-Townsend, A. (1978) Efficacies of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacology Bulletin, 14, 20–22.Google Scholar
Enna, S. J., Stern, L. Z., Wastek, G. J. & Yammura, H. J. (1977) Neurobiology and pharmacology of Huntington's disease. Life Sciences, 20, 205–212.Google Scholar
Fann, W. E., Stafford, J. R., Malone, R. L., Frost, J. D. & Richman, B. W. (1977) Clinical research techniques in tardive dyskinesia. American Journal of Psychiatry, 134, 759–762.Google Scholar
Friis, T., Rosted Christensen, T. & Gerlach, J. (1983) Sodium valproate and biperiden in neuroleptic-induced akathisia, Parkinsonism and hyperkinesia Acta Psychiatrica Scandinavica, 67, 178–187.Google Scholar
Gardos, G., Cole, J. O. & La Brie, R. (1977) The assessment of tardive dyskinesia. Archives of General Psychiatry, 34, 1206–1212.Google Scholar
Gardos, G., Cole, J. O. & Tansy, D. (1978) Withdrawal syndromes associated with antipsychotic drugs. American Journal of Psychiatry, 135, 1321–1324.Google Scholar
Gerlach, J. (1977) The relationship between Parkinsonism and tardive dyskinesia. American Journal of Psychiatry, 134, 781–784.Google Scholar
Gerlach, J., Rye, T. & Kristjansen, P. (1978) Effect of baclofen on tardive dyskinesia. Psychopharmacology, 56, 145–151.Google Scholar
Gibson, A. C. (1978) Sodium valproate and tardive dyskinesia. British Journal of Psychiatry, 133, 82.Google Scholar
Hammond, E. J., Wilder, B. J. & Bruni, J. (1981) Central actions of valproic acid in man and in experimental models of epilepsy. Life Sciences, 29, 2961–2574.Google Scholar
Jeste, D. V. & Wyatt, R. J. (1979) In search of treatment for tardive dyskinesia: review of the literature. Schizophrenia Bulletin, 5, 251–293.Google Scholar
Jeste, D. V. & Wyatt, R. J. (1982) Therapeutic strategies against tardive dyskinesia. Archives of General Psychiatry, 39, 803–816.Google Scholar
Kelly, J. S. & Beart, P. M. (1975) Amino acid receptors in the CNS. II: GABA in supraspinal regions. In Handbook of Psychopharmacology (eds. L. L. Iverson & S. H. Synder) Vol. 4. New York: Plenum Press.Google Scholar
Kidger, T., Barnes, T. R. E., Trauer, T. & Taylor, P. J. (1980) Subsyndromes of tardive dyskinesia. Psychological Medicine, 10, 513–520.Google Scholar
Krawiecka, M., Goldberg, D. & Vaughan, M. (1977) A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica, 55, 299–308.Google Scholar
Lakke, J. P. W. & Teelken, A. W. (1976) Amino acid abnormalities in the cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders. Neurology, 26, 489–493.Google Scholar
Lautin, A., Angrist, B., Stanley, M., Gershon, S., Heckl, K. & Karabath, M. (1980) Sodium valproate in schizophrenia: some biological correlates. British Journal of Psychiatry, 137, 240–244.Google Scholar
Linnoila, M., Viuka, M., Hietala, O. (1976) Effect of sodium valproate on tardive dyskinesia. British Journal of Psychiatry, 129, 114–119.Google Scholar
Lloyd, K., Dreksler, S. & Bird, E. (1977) Alterations in H-GABA binding in Huntington's chorea. Life Sciences, 21, 747–754.Google Scholar
Mackay, A. V. P. & Shepherd, G. P. (1979) Pharmacotherapeutic trials in tardive dyskinesia. British Journal of Psychiatry, 135, 489–499.Google Scholar
McGeer, P. L. & McGeer, E. G. (1976) Enzymes associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. Journal of Neurochemistry, 26, 65–76.Google Scholar
Meldrum, B. S. & Chapman, A. G. (1983) The mechanism of action of sodium valproate: recent advances. British Journal of Clinical Practice, Supplement 27, 136–141.Google Scholar
Moore, D. C. & Bowers, M. B. (1980) Identification of subgroup of tardive dyskinesia patients by pharmacologic probes. American Journal of Psychiatry, 137, 1202–1205.Google Scholar
Nair, N. V. P., Lal, S. & Guyda, H. (1980) Effects of GABAergic drugs on nigrostriatal and hypothalamic pituitary dopaminergic systems. Brain Research Bulletin, 5 (Supplement 2), 427–431.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, 212, 11–19.Google Scholar
Walters, J. R., Roth, H. H. & Aghajanian, G. K. (1973) Dopaminergic neurones: similar biochemical and histological effects of gammahydroxytbutyrate and acute lesions of the nigrostriatal pathways. Journal of Pharmacology and Experimental Therapeutics, 186, 630–639.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.